The Partnership Will Leverage the National Laboratory Network of EmeritusDX to Offer URO17 to Urologists Across the Country
IRVINE, Calif., and SAN JOSE, Calif., Nov. 7, 2022 /PRNewswire-PRWeb/ -- EmeritusDX and KDx Diagnostics announced today the partnership to provide the URO17 test for the detection of bladder cancer. URO17 is a non-invasive urine test with high sensitivity and negative predicted value (NPV) that can be used to determine the status of active bladder cancer and to improve patient diagnosis. This is also likely to improve the treatment path as URO17 is also now available as a Laboratory Developed Test (LDT) in the United States. EmeritusDX will offer URO17 testing to Urology practices across the country.
With over 85,000 new cases of bladder cancer in the United States every year the most common symptom of bladder cancer is hematuria, or blood in the urine, and patients with hematuria need to be subjected to invasive cystoscopic procedures even though a large majority of patients with micro-hematuria will not have bladder cancer. The URO17 test, and its high sensitivity and NPV for bladder cancer, will assist in ruling these patients out for unnecessary cystoscopy and its invasive procedure and in turn reduce the work-up.
"We are very excited to partner with EmeritusDX, a premier cancer diagnostics and information company in the US, to make our URO17 test and information available to their network of urologists. Through EmeritusDX, urologists will have direct access to ordering URO17 Laboratory Developed Test for patients at risk of bladder cancer," says Sholeh Jahanfard, President of KDx Diagnostics Inc.
"EmeritusDX is thrilled to present this additional test offering to the clients we serve. The URO17 LDT test adds efficiency and precision to the care of patients with bladder cancer. EmeritusDX is dedicated to expanding our services to ensure patient care is served and clinical outcomes are improved," says Robert Embree, Chief Executive Officer of EmeritusDX.
URO17 LDT is currently validated and available for ordering through EmeritusDX
About EmeritusDX
EmeritusDX is a cancer diagnostics and information company. Our expertise is in delivering actionable clinical information. Within our world-class laboratory, we perform testing that guides the diagnosis and treatment of cancer patients. Our partners include hospital and private pathology practices, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.
About KDx Diagnostics Inc.
Founded in 2017, KDx is focused on developing non-invasive cancer tests to improve early detection and therapy decisions in cancer. The URO17 bladder cancer test developed by KDx may prove to be the most sensitive and specific for bladder cancer developed to date. KDx plans to develop tests based on the same biomarker for other platforms and sample types and expand its product line into other cancer diagnostic tests. URO17 is available as LDT in the U.S.
If you would like more information about this topic, please call 800-959-2846 or email [email protected]
Media Contact
Chateau Lafite, KPA, EmeritusDX, 1 800-959-2846, [email protected]
SOURCE EmeritusDX
Share this article